Home
>
National Drug Code (NDC)
>
Combivir
Combivir - 11819-359-14 - (Lamivudine and Zidovudine)
Drug Information of Combivir
| Product NDC: | 11819-359 |
| Proprietary Name: | Combivir |
| Non Proprietary Name: | Lamivudine and Zidovudine |
| Active Ingredient(s): | 150; 300 mg/1; mg/1 & nbsp; Lamivudine and Zidovudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Combivir
| Product NDC: | 11819-359 |
| Labeler Name: | HHS/Program Support Center/Supply Service Center |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020857 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19970930 |
Package Information of Combivir
| Package NDC: | 11819-359-14 |
| Package Description: | 14 TABLET, COATED in 1 BOTTLE (11819-359-14) |
NDC Information of Combivir
| NDC Code | 11819-359-14 |
| Proprietary Name | Combivir |
| Package Description | 14 TABLET, COATED in 1 BOTTLE (11819-359-14) |
| Product NDC | 11819-359 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Lamivudine and Zidovudine |
| Dosage Form Name | TABLET, COATED |
| Route Name | ORAL |
| Start Marketing Date | 19970930 |
| Marketing Category Name | NDA |
| Labeler Name | HHS/Program Support Center/Supply Service Center |
| Substance Name | LAMIVUDINE; ZIDOVUDINE |
| Strength Number | 150; 300 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
